Trials / Withdrawn
WithdrawnNCT00112060
A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase I/II, Open-Label, Multicenter Study of Single Agent PT-523 in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Spectrum Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase I/II, multi-centered, non-randomized trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PT-523 for Injection |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2005-05-30
- Last updated
- 2014-03-31
Locations
13 sites across 2 countries: United States, Russia
Source: ClinicalTrials.gov record NCT00112060. Inclusion in this directory is not an endorsement.